CA125值與卵巢癌預後的關聯

Prognostic Value of Normal Range CA 125 in Advanced Ovarian Cancer

李耀泰(Yiu-Tai Li) ； 陳福民(Fu-Min Chen) ； 沈仁達(Jen-Ta Shen) ； 李文琮(Wen-Psung Lee) ； 郭宗正(Tsung-Cheng Kuo)

《中華民國婦癌醫學雜誌》 2012年1期 (2012/01) Pp. 1-10

https://doi.org/10.7010/JGO.201201.0001

摘要

大部分的晚期上皮性卵巢癌患者，經過減積手術和化學治療後，暫時都有很好的臨床效果，可達到完全效應，不幸的是，這些患者最後仍多會復發和死亡。通常對上皮性卵巢癌的治療效果及復發，CA125值被視為是最標準的偵測方法。最近研究顯示，在晚期上皮性卵巢癌患者，經減積手術加3至6次療程的化學治療後，測量CA125的值，可以有效預測是否會復發，通常如CA125最低值能≦12U/mL預後較好，值＞12U/mL則預後較差。

關鍵字

上皮性卵巢癌 ； CA125 ； 預後

並列摘要

The majority of patients with advanced ovarian cancer will have a complete clinical response to primary debulking operation and chemotherapy. Unfortunately, most patients will develop a subsequent relapse and finally succumb to progressive disease. Usually, the utilization of serum CA 125 level is considered standard of care for monitoring response to treatment for epithelial ovarian cancer recurrence. The baseline CA 125 level after primary surgery and 3 or 6 cycles of chemotherapy strongly predicts the risk of subsequent relapse. Generally, patients with premaintence baseline CA 125 values approximately≦12 U/mL have a superior progressive free survival and overall survival compared with higher levels in the normal CA 125 range.

並列關鍵字

epithelial ovarian cancer ； CA 125 ； prognosis